Obsidian Therapeutics has raked in $115 million to realize the long-unfulfilled therapeutic promise of tumor-infiltrating lymphocytes (TILs). The series B gives Obsidian a shot at showing whether freeing TILs from IL-2 can finally unleash power that research has hinted at for almost 30 years. Researchers at the NIH began revealing the therapeutic potential of TILs […]

Our apologies to those who still wince when reminded of the following figures. But because these data illustrate successes, or lack thereof, of clinical trials from the past, they serve as an outcomes baseline for the future: Will future outcomes be based on the types of protocols used in the COVID-19 vaccine trials, or will […]

The brainchild of serial biotech entrepreneur Michael Gilman, Obsidian is hoping to bring something new to the party with “on-switch” technology for a range of potential drug applications. Obsidian now has a new treasure chest to play with — and an IPO feels only a fingertip away. Obsidian closed a $115 million Series B with […]